StemCyte Inc.
生物技术研究
Nangang District，Taipei City 2,761 位关注者
It is not just saving cord blood. It is about Saving Lives.
关于我们
StemCyte is dedicated to expanding the applications of cell therapy to address currently incurable diseases, paving the way for a healthier future through its guiding principle: “Better Cell, Better Life.” Founded in the United States in 1997, StemCyte has established a strong presence in Taiwan and India. To date, it has built a public cord blood bank with over 36,000 units, making it the largest in scale globally, with unparalleled racial diversity and superior quality. StemCyte is also among the few biotechnology companies that operate both public and private cord blood banks. Over the past 20 years, StemCyte has provided more than 2,300 cord blood units to over 350 transplant centers worldwide, supporting the treatment of various diseases. In November 2024, StemCyte became the first private company in the world to obtain FDA approval for a cord blood biologics license. Moving forward, StemCyte will continue its commitment to advancing the development of cord blood cell therapies, ensuring that physicians and patients around the globe have access to safe and effective cell therapy resources. For more information, please visit https://stemcytebio.com/.
- 网站
-
https://stemcytebio.com/
StemCyte Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Nangang District，Taipei City
- 类型
- 私人持股
- 创立
- 1997
- 领域
- Private/Family Cord Blood and Cord Lining Storage、Public Donation Cord Blood Banking和Provide Unrelated Cord Blood Products
地点
StemCyte Inc.员工
动态
-
?? Happy Lunar New Year! ?? Thank you for supporting us as we celebrated FDA approval for RegeneCyte this year! Your encouragement fuels our innovation and progress. As the Lunar New Year approaches, we’re excited to continue advancing our cell therapy products, bringing hope and healing to even more patients in need. Wishing you a wonderful and prosperous year ahead! ??農曆新年快樂！ ?? 感謝您今年與永笙一同見證 RegeneCyte 獲得美國 FDA 藥證的精彩時刻！您的支持是我們持續創新的力量。 新的一年，我們將繼續推動再生醫學與細胞治療的發展，為更多生命帶來希望。祝蛇年吉祥，幸福安康！ ? #StemCyte #HappyNewYear #CellTherapy #永笙生技 #新年快樂 #細胞治療
-
-
?? Innovating Cell Therapy: REGENECYTE? Achieves FDA BLA Approval ?? In November 2024, StemCyte received FDA BLA approval for our cell therapy product, REGENECYTE?. ?? This achievement marks a significant step forward in advancing cell-based treatments. We extend our heartfelt thanks to Joanna Sadowska, PhD, EMBA for recognizing and sharing this major milestone with us! At StemCyte, we are continuing to move forward. ?? Our journey involves actively exploring collaborations to expand the applications of REGENECYTE?. Together, let’s push the boundaries of what’s possible in regenerative cell therapy! ?? 創新細胞治療：REGENECYTE? 獲得 FDA BLA 核准 ?? 2024 年 11 月，永笙生技的細胞治療產品 REGENECYTE? 榮獲美國 FDA BLA 核准！?? 這是永笙推動細胞治療領域的一大重要進展。我們誠摯感謝 Joanna Sadowska 博士分享並見證這項重要里程碑！ 永笙生技將持續邁步向前。?? 我們積極尋求合作機會，持續拓展 REGENECYTE? 的應用，共同推動再生醫療與細胞治療的更多可能性！
Pharma and Biotech Market Research | Medical Communications | Science Liaison | Medical Affairs
?????????? ???????? ?????? ???????? ?????????????????? ???????? ???????? ???????????????? ???? 2024? 2024 was definitely a good year for CGT in terms of novel FDA approvals. The FDA approved 9 new cellular and gene therapy products. Here is the list: ? AMTAGVIL - Iovance Biotherapeutics, Inc. Biotherapeutics ? LENMELDY - Orchard Therapeutics - U.S. ? BEQVEZ - Pfizer ? TECELRA - Adaptimmune ? AUCATZYL - Autolus Therapeutics ? KEBILDI - PTC Therapeutics, Inc. ? REGENECYTE - StemCyte Inc., ? RYONCIL - Mesoblast Limited ? SYMVESS - Humacyte Apart from these, several products received approval for new indications, such as: ? CASGEVY (Vertex Pharmaceuticals and CRISPR Therapeutics) for transfusion-dependent ?-thalassemia (TDT). ? BREYANZI (Juno Therapeutics, Inc., Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). ? ELEVIDYS (Sarepta Therapeutics) for the treatment of DMD in patients who are non-ambulatory. ?????????? ???? ?????????? ?????? ?????? ???????? ???????????????? ???????????????? ???? ?????? ???????? ?????? ???????? ?????????????????? ?????????? ???? 2024? #cgt #biotech #pharma #innovation #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo ?? ?? ???????? ???????????????? ?????? ?????????????????????????? ???????????? ?????????? ?????????? ?????? ???????????????????? ?? Share this if you find it interesting ?? Follow for insights you won't want to miss ?? DM me to increase your visibility, grow your business, and generate leads
-
-
? Happy New Year from StemCyte! ? As we welcome 2025, we remain committed to driving innovation in cell therapies, cellular materials supply, and cell products and services, transforming lives and advancing health worldwide. Thank you for your trust and support throughout the past year. Wishing you and your loved ones a year filled with health, happiness, and prosperity. Together, let’s shape a brighter future! ? 永笙生技祝您新年快樂！ ? 迎接2025，我們滿懷希望與決心，持續推動細胞新藥、細胞供應，與細胞服務，用創新改變更多生命、守護更多健康。 感謝您過去一年的支持與信任，願新的一年，您和摯愛的家人擁有更多健康幸福！讓我們共創更美好的未來！ #StemCyte #HappyNewYear #CellTherapy
-
-
??Merry Christmas from Everlife Biotech! ?? During this festive season, we at StemCyte would like to express our heartfelt gratitude for your support and trust! ? In 2024, our cord blood cell therapy product RegeneCyte successfully received FDA approval, marking a major milestone in our journey in cell therapy. Looking ahead, we will continue to innovate and bring the benefits of cell therapy to more lives. ?? Wishing you and your loved ones a joyful and healthy holiday season! ?? 永笙生技祝您聖誕快樂！ ?? 在這溫馨的佳節，永笙感謝您對我們的支持與信任！? 祝福您與摯愛的家人擁有充滿愛與健康的聖誕佳節！ 2024年，永笙臍帶血細胞新藥 RegeneCyte 成功獲得美國 FDA 核准藥證，是永笙在細胞治療領域的重要里程碑；未來，我們將持續創新研發，以細胞治療技術幫助更多生命??
-
-
感謝「先進醫療臨床策略、應用及挑戰研討會」的邀請，與CellTech Accelerator 的分享！
就在上週，由我們創笙加速器、中華民國製藥發展協會、環球生技共同主辦的「先進醫療臨床策略、應用及挑戰研討會」圓滿落幕！回顧此次活動，我們不僅見證了細胞治療領域的最新進展，也深刻感受到來自各方專家的熱情與參與者的高度關注。這些寶貴經驗讓我們對未來醫療科技的發展充滿期待，也更加堅信台灣在全球醫療創新領域中具有巨大的潛力。 研討會中，經濟部產業技術司簡任技正戴建丞博士深入分析了細胞治療產業的發展現狀與未來策略，幫助我們更加了解台灣在此領域的優勢與挑戰。隨著產業技術的快速進步，如何在激烈的國際市場中找到突破口，成為各界關注的焦點。這不僅是技術層面的挑戰，更涉及如何在政策支持與資源配置上形成良性循環，從而促進整體產業的發展。 永生細胞 StemCyte Inc. 董事長暨執行長李冬陽博士 Tong-Young Lee 的精彩分享讓我們深受啟發。他分享了RegeneCyte臍帶血細胞療法的臨床成果，展示了創新醫療技術在對抗長新冠症候群中的巨大潛力。這樣的研究突破無疑是台灣生技領域的一大亮點，我們為能在全球舞台上看到來自台灣的創新而感到無比驕傲。 此外，沛爾生醫副產務長張碩修博士 Shuo-Hsiu Chang 對 CAR-T 免疫細胞療法的深入解析，讓我們更清楚地理解這項技術在癌症治療中的前景與挑戰。隨著臨床應用的推進，CAR-T療法在國際間的發展迅速，但如何將這項技術本地化並提升患者療效，仍是未來的關鍵課題。 我們相信，本次研討會不僅是一場學術交流，更是一個推動醫療科技進步的重要契機。透過與會專家的深入對話，我們希望激發更多創新思維，並進一步促進產學合作與技術轉化。我們創笙加速器將持續推動醫療技術的創新與應用，並計畫未來舉辦更多此類專業活動，攜手業界夥伴，推動台灣在全球生物醫藥領域的領先地位。 此次活動也得到了多家企業的慷慨支持：台康生技股份有限公司 EirGenix, Inc.、尚博生物科技 Cell-Bio Biotechnology Co., Ltd.、TailorMed International Courier Ltd.、博克科技股份有限公司、明生生物科技股份有限公司 Mithra Biotechnology、永昕生醫 Mycenax Biotech Inc.、恩凱生物科技、岑祥股份有限公司。我們由衷感謝各界的共同努力與參與，讓這場具有深遠影響的研討會得以順利舉行。我們期待未來能繼續與各方攜手合作，推動醫療創新、改善患者生活品質，為全球健康事業貢獻更多力量。 ##BioTech #CellTherapy #CordBlood #Innovation #Taiwan #Healthcare
-
-
-
-
-
+1
-